Trial record 1 of 139 for:    Open Studies | "Burns"
Previous Study | Return to List | Next Study

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by American Scitech International.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Johnson & Johnson
Information provided by:
American Scitech International
ClinicalTrials.gov Identifier:
NCT00812513
First received: December 19, 2008
Last updated: July 19, 2011
Last verified: July 2011
  Purpose

Platelet Derived Growth Factor (PDGF) is a potent mitogen for a wide range of cell types including fibroblasts, smooth muscle and connective tissue. Recombinant human platelet derived growth factor (R-Pdf/Gbb) has biologic activity similar to endogenous platelet derived growth factor (PDGF). Biologic activity of PDGF includes encouraging chemotaxis and proliferation of cells responsible for wound repair and it augments production of granulation tissue.

The growth factor rhPDGF is found effective in patients having diabetic foot ulcer grade III and IV. The nature of wounds in the third degree burns is similar so far as healing process is concerned.

The purpose of this study is to test the hypotheses that the application of R-Pdf/Gbb 0.01% gel on the third degree thermal and electrical burns will heal these wounds within 3 months and there will be improvement in general condition of the patients without any complications.


Condition Intervention Phase
Burns
Electric Burns
Drug: R-Pdf/Gbb 0.01% gel
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Efficacy of Recombinant Human Platelet-derived Growth Factor (R-Pdf/Gbb) in Healing Wounds Caused by Third Degree Thermal and Electrical Burns.

Resource links provided by NLM:


Further study details as provided by American Scitech International:

Primary Outcome Measures:
  • Complete healing of the third degree burn wound. [ Time Frame: 3 months. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Improvement in general condition of the study subjects without any complications. [ Time Frame: 3 months. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: July 2011
Estimated Study Completion Date: April 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: R-Pdf/Gbb 0.01% gel
    rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
    Other Name: Recombinant human platelet-derived growth factor
Detailed Description:

The R-Pdf/Gbb is recombinant human platelet-derived growth factor. It has been demonstrated that rhPDGF is effective in enhancing wound healing.

OBJECTIVE: The primary objective of the study is to determine the efficacy of R-Pdf/Gbb gel in treating wounds caused by III degree thermal and electrical burns.

HYPOTHESIS 1: That the applications of R-Pdf/Gbb 0.01% gel on III degree thermal and electrical burns will heal these wounds within 3 months.

HYPOTHESIS 2: Subjects, who having III degree thermal and electrical burns with the treatment of R-Pdf/Gbb 0.01% gel, will show improvement in general condition without any complications.

We aim to test these hypotheses by evaluating the clinical outcome in about 120 patients after three months of treatment with R-Pdf/Gbb 0.01% gel applied once daily.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients willing to sign Informed consent.
  • Patients of both genders.
  • Patients between ages of 18 to 75 years.
  • Patients having third degree wounds caused by thermal and electrical burns.
  • Patients not willing to undergo skin grafting.
  • Patients with multiple wounds are considered but each burn wound surface area will be less than 1-8 cm2.
  • Wounds with adequate perfusion as assessed with the help of laser Doppler flowmeter.

Exclusion Criteria:

  • Patient refuses to sign informed consent.
  • Burnt wounds severity less/more than III degree (i.e. I, II, IV degree burns).
  • Patients having known neoplasm at the site of application.
  • Patients with low serum proteins.
  • Patients with uncontrolled hyperglycemia.
  • Patients who are taking Ibuprofen.
  • Patients with known hypersensitivity to parabens.
  • All other burns except thermal and electrical burns.
  • Neurological or psychiatric pathologies.
  • Women who are pregnant or nursing and women of child bearing age, who are not taking contraceptives or not willing to use them for the period of treatment.
  • Local or systemic infection
  • Conditions that would interfere with wound healing (diabetes, hypertension, inflammatory diseases treated by corticoids)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00812513

Locations
United States, New Jersey
Saint. Barnabas Medical Center, The Burn Center Not yet recruiting
Livingston, New Jersey, United States, 07039
Contact: Nani E Mansour, MD    908-941-5480    rgreywal@americanscitech.com   
Contact: Ratna Grewal, MD    908-941-5480    rgreywal@americanscitech.com   
Sponsors and Collaborators
American Scitech International
Johnson & Johnson
Investigators
Study Chair: Ratna Grewal, MD American Scitech International- eCRO
Principal Investigator: Nani E Mansour, MD Saint Barnabas Medical Center, The Burn Center
  More Information

No publications provided

Responsible Party: Dr. R. Grewal, American Scitech International
ClinicalTrials.gov Identifier: NCT00812513     History of Changes
Other Study ID Numbers: ASI-TEBII1208
Study First Received: December 19, 2008
Last Updated: July 19, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by American Scitech International:
rhPDGF-BB
Platelet derived growth factor
Burns
Thermal burns
Electric burns

Additional relevant MeSH terms:
Burns
Burns, Electric
Wounds and Injuries
Electric Injuries
Mitogens
Platelet-derived growth factor BB
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Angiogenesis Inducing Agents
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 16, 2014